

# FACT SHEET


## COMPANY PROFILE

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and MDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec AG's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. With about 3,000 employees, the Group generated revenue of € 1,280.9 million in financial year 2017/2018 (to 30 September).


The Group's head office is in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries.

For more information visit our website at: [www.meditec.zeiss.de](http://www.meditec.zeiss.de)

## SHARE CHART



## SHAREHOLDER STRUCTURE



## MANAGEMENT BOARD



**Dr. Ludwin Monz**  
CEO



**Justus Felix Wehmer**  
CFO



**Jan Willem de Cler**

## SUPERVISORY BOARD

> **Prof. Dr. Michael Kaschke**

> **Thomas Spitzenpfeil**

> **Jörg Heinrich**

> **Dr. Markus Guthoff**

> **Cornelia Grandy**

> **Tania von der Goltz**

## STOCK FUNDAMENTALS

ISIN	DE0005313704
WKN	531370
Share type	Ordinary
Bloomberg Code	AFX@GR
Reuters Code	AFXG.DE
Ticker	AFX
Branch	Medical Technology
Index	MDAX, TecDAX
Segment	Prime Standard
Last Dividend	0.55 EUR (Proposal, 2017/18)
No. of shares	89,440,570
Market Cap	EUR 7.04 bn
52 week high	84.55 EUR
52 week low	48.60 EUR

## FINANCIAL CALENDAR

<b>Mar 19, 2019</b>	Annual General Meeting
<b>May 06, 2019</b>	Publication half-yearly financial report
<b>Aug 09, 2019</b>	Publication quarterly statement (call-date Q3)
<b>Dec 06, 2019</b>	Publication annual financial report

# FACT SHEET

## HIGHLIGHTS ON A YEARLY BASIS<sup>1</sup>

	2017/18 <sup>2</sup>		2016/17 <sup>2</sup>		2015/16 <sup>2</sup>	
	€k	%	€k	%	€k	%
Revenue	1,280,860	100	1,189,896	100	1,088,365	100
Research and development expenses	159,628	12.5	145,792	12.3	123,406	11.3
EBIT	197,130	15.4	180,830	15.2	154,332	14.2
Consolidated profit <sup>3</sup>	126,230	9.9	135,778	11.4	99,970	9.2
Earnings per share <sup>4</sup> (in €)	1.41		1.57		1.21	
Dividend per share (in €)	0,55 <sup>5</sup>		0,55 <sup>5</sup>		0,42 <sup>5</sup>	
Cash flows from operating activities	187,207		37,732		111,770	
Cash flows from investing activities	(28,874)		(55,931)		77,332	
Cash flows from financing activities	(157,237)		14,494		(195,021)	
Total assets	1,662,052	100	1,623,108	100	1,247,730	100
Property, plant and equipmen	62,632	3.8	58,696	3.6	64,509	5.2
Equity	1,314,634	79.1	1,241,735	76.5	851,163	68.2
Net cash <sup>6</sup>	670,000	40.3	565,000	34.6	334,582	26.8
Employees at end of reporting period (30 September)	3,048		2,958		2,910	

1 End of September 30th

2 Consolidated Financial Statements (IFRS)

3 Before non-controlling interests

4 Profit/(loss) per share attributable to the shareholders of the parent company in the fiscal year

5 Amount proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG

6 Cash and cash equivalents plus treasury receivables from/payables to the treasury of Carl Zeiss AG

### Carl Zeiss Meditec AG

Göschwitzer Str. 51-52  
07745 Jena  
Deutschland  
[www.zeiss.de/meditec-ag/ir](http://www.zeiss.de/meditec-ag/ir)

[investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)

### Contact Investor Relations

**Sebastian Frericks**  
Director Investor Relations  
Phone: +49 (0) 36 41 / 2 20 -1 16  
Fax: +49 (0) 36 41 2 20 - 1 17  
E-Mail: [investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)